GlassScriptPhysician profile
Kiranchandra Patel
NPI 1053416453
$3,445.95
in general payments reported to CMS, 2019-2025
29 companies · $387 in 2025
The $387 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $331 · 2020: $81.79 · 2021: $567 · 2022: $682 · 2023: $621 · 2024: $777 · 2025: $387.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,785.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,785.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,159.19 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $306.79 | 2019-2025 | Airsupra, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $239.54 | 2022-2025 | |
| Abbvie INC. | $215.44 | 2019-2025 | |
| Exact Sciences Corporation | $159.17 | 2023-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $159.15 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Pfizer INC. | $152.51 | 2021-2024 | |
| Boston Scientific Corporation | $141.43 | 2019-2021 | |
| Amgen INC. | $124.68 | 2023-2025 | Otezla, Repatha, Otezla |
| Abbott Laboratories | $116.09 | 2023-2024 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $75.38 | 2021-2024 | Gardasil, Gardasil 9, Capvaxive |
| Mylan Specialty L.P. | $66.47 | 2021 | |
| Horizon Therapeutics Plc | $57.50 | 2023 | Krystexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.56 | 2019-2025 | Ofev |
| Genentech USA, INC. | $52.93 | 2019-2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $47.18 | 2019-2024 | Spravato |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $41.77 | 2021-2022 | |
| Edwards Lifesciences Corporation | $39.32 | 2023-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Takeda Pharmaceuticals U.S.A., INC. | $29.00 | 2020-2023 | Trintellix |
| Biohaven Pharmaceutical Holding Company LTD. | $26.93 | 2022 | |
| Abiomed | $26.42 | 2025 | |
| Eisai INC. | $25.87 | 2024 | |
| Optinose US, INC. | $25.04 | 2021 | |
| Neuronetics, INC. | $23.62 | 2020 | |
| Glaxosmithkline, LLC. | $19.03 | 2019 | |
| Integra Lifesciences Corporation | $16.89 | 2024 | Trudi Probe, Relieva Spinplus Nav, Inspira Air |
| Idorsia Pharmaceuticals US INC | $15.15 | 2023 | Quviviq |
| Astellas Pharma US INC | $14.93 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $13.97 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kiranchandra Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.